Quilt Health Secures $6M Seed Funding to Modernize Clinical Trial Access for Complex Diseases
核心洞察
Quilt Health (搜索), a digital health company focused on bridging treatment access gaps for complex diseases, successfully closed a $6 million seed funding round, bringing total funding to $8 million.
The company addresses critical clinical trial recruitment challenges, with more than 70% of trials failing to meet enrollment thresholds, particularly in rare disease research where patient pools are small and hard to reach.
Quilt Health (搜索)'s AI-powered platform integrates multiple data sources to surface key patient characteristics and outcomes, supporting clinical workflows and improving trial efficiency for pharmaceutical sponsors, research sites, and patients.
Quilt Health (搜索), a digital health company dedicated to bridging gaps in treatment access for complex diseases, has successfully closed a $6 million seed funding round, bringing its total funding to $8 million. The round was led by MaC Venture Capital (搜索) and Underscore Ventures (搜索), with participation from Meridian Street Capital (搜索), BoxGroup (搜索), Watershed VC (搜索), and Coalition Operators (搜索).
Founded with an initial focus on sickle cell disease (搜索), the company plans to use the new capital to rapidly expand into other hematologic, neurological, and cardiovascular disorders (搜索), addressing the broader challenges faced by millions of people living with complex conditions.
Addressing Critical Clinical Trial Recruitment Challenges
Quilt Health (搜索) is modernizing clinical trial access by expanding the number and type of sites included in trials and bridging the gap between real-world care and research. Despite decades of innovation in drug development, clinical trials remain plagued by an outdated and inefficient recruitment process. This problem is magnified in rare disease research, where patient pools are small and hard to reach, resulting in more than 70% of trials failing to meet their enrollment thresholds.
The company's technology addresses this challenge by supporting clinical workflows through the integration of multiple data sources and applying AI to unstructured data to surface key patient characteristics and outcomes. Combined with patient engagement tools, the platform keeps patients and clinicians connected between visits to improve care and make cutting-edge treatments more accessible.
Comprehensive Platform Benefits
Quilt Health (搜索)'s platform is designed to benefit the entire clinical trial ecosystem across multiple stakeholders:
For Pharmaceutical Sponsors: Quilt's network and platform accelerate trial execution, reduce operational costs, and support more representative patient enrollment, which is a critical factor in improving trial diversity.
For Research Sites and Clinicians: They gain access to streamlined workflows, enhanced data collection tools, and hands-on recruitment support, allowing them to focus more on delivering high-quality care and research.
For Patients: The platform's engagement tools keep patients and clinicians connected between visits, improving care and making cutting-edge treatments more accessible.
Strategic Partnership with NASCC
In addition to its funding, Quilt Health (搜索) recently announced a partnership with the National Alliance of Sickle Cell Centers (搜索) (NASCC) in March 2025. With more than 115 sickle cell centers represented, NASCC provides Quilt Health with a national network for combining research and patient care.
"Together, we are creating a more effective, national, patient-centered ecosystem that speeds up the path to market for life-saving treatments," said Andy Ellner, Founder and CEO of Quilt Health (搜索).
Julie Kanter, Founder and President of NASCC, expressed enthusiasm for the partnership: "We are delighted to partner with Quilt Health (搜索). By matching a purpose built technology solution with the needs of a network of world-class sickle cell centers including multidisciplinary teams of clinicians and researchers, we will drive towards improving the quality OF care and access TO care for people living with Sickle Cell Disease (搜索)."
Investment and Expansion Plans
The $6 million in seed funding will be utilized to accelerate product development, fuel R&D, and expand the Quilt Health (搜索) team. The company will also focus on partnering with high-quality health systems in regions of the country that have not traditionally benefited from major life sciences investment.
"Quilt Health (搜索) is tackling one of the most critical barriers in clinical research-patient recruitment and retention-by fundamentally reshaping how trials operate," said Marlon Nichols, Managing Partner at MaC Venture Capital (搜索). "Quilt is not just improving healthcare efficiency but reshaping the entire landscape of rare disease research. The team has the potential to be a revolutionary force in providing life-altering therapies to people who need them most thanks to its scalable methodology and patient-first approach."
Brian Devaney, Partner at Underscore VC, added: "The Quilt Health (搜索) founding team stands out even in Boston's robust healthcare innovation ecosystem. Andy and Jazmine's proven experience building trust with stakeholders across the healthcare ecosystem makes them uniquely positioned to build a valuable solution for patients, providers, and life sciences companies alike."
Founded in 2024, Quilt Health (搜索) is initially focused on sickle cell disease (搜索), described as the most common rare disease in the U.S., affecting African, Middle Eastern, and Mediterranean populations.